TickerTalks
Browse all tickers →
TickerTalks›$MTD
MTMTD

Mettler-Toledo International Inc.

$MTD·$31B·Medical - Diagnostics & Research·Healthcare
$1642.42+2.1%YTD+14.2%1Y+23.5%
Price updated 1m ago·X counts updated 4d ago
MTMTD
$MTDMettler-Toledo International Inc.
$1,642.42+2.06%31 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

Top X posts

The complete picture of $MTD on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

31X posts · last 7 days
Sep 28Oct 11
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $MTD's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $MTD — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Proven numbersWinding up for a moveAI verdict · as of 2026-10-02

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Mettler-Toledo is a quality precision-instrument compounder with 28% operating margin — Nov 5 earnings is the test.

Mettler-Toledo makes precision instruments — lab balances, weighing systems, mass spectrometry, and process analytics for lab, industrial, and food-safety customers.

  • The economics are elite: Q1 revenue +7.2% YoY at a 28% operating margin and ROIC of 36.1% — top-decile capital efficiency with a highly recurring consumables-and-services mix.
  • At 26.8x PE and 5.7x sales the valuation is premium — Mettler consistently trades at this multiple because the business is one of the few genuinely-wide-moat precision-instrument franchises.
  • 52-week range position is 86% with vol at 79% of average — upper range on quiet volume, which is sustainable continuation into the Nov 5 print.

Nov 5 Q3 is the gate — any continued organic revenue growth plus margin expansion extends the move. A soft lab-end-market print or margin compression and the stock gives back some gain.

What to watch: Nov 5 Q3 — organic revenue growth, lab and industrial end-market mix, operating-margin trajectory, and FY27 guide. A margin compression is the clear invalidator.

On the calendar: 2026-11-05 — Q3 earnings

Read the AI verdict on $MTD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes precision laboratory balances, analytical instruments, and process weighing systems for pharma and food industries.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $MTD.

Medical - Diagnostics & Research · Healthcare

Genetic testing, liquid biopsy, and multi-cancer early detection (MCED) platforms are growing through direct-to-consumer and employer wellness channels; reimbursement coverage expansion by CMS and commercial payers is the adoption bottleneck. Lab volume normalization post-COVID is complete; growth is now driven by novel test launches and test menu expansion for chronic disease management.

What this means for $MTD

Neutral — Makes precision laboratory balances, analytical instruments, and process weighing systems for pharma and food industries.

Industry benchmark

19-name peer basket
+36.8%YTD
+55.1%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
26.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
36.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
28.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
3.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-6.1%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
57.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
-53.2Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$11.46$10.85+5.6%
Q1 2026May 7, 2026$8.91$8.71+2.3%
Q4 2025Feb 5, 2026$13.36$12.80+4.4%
Q3 2025Nov 6, 2025$11.15$10.66+4.6%
Next earningsThu, Nov 5·consensus EPS $12.12

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$947.1M+7.2%58.7%26.0%$8.35$122.4M
Q4 FY25$1.1B+8.1%58.0%30.4%$14.02$184.1M
Q3 FY25$1.0B+7.9%57.2%28.2%$10.60$274.9M
Q2 FY25$983.2M+3.9%57.2%27.0%$9.77$212.5M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$4.2B$4.2B – $4.3B$47.33$47.23 – $47.5310
FY27$4.4B$4.4B – $4.5B$51.71$51.29 – $51.9910
FY28$4.7B$4.6B – $4.7B$57.22$55.84 – $59.299
FY29$4.9B$4.9B – $4.9B$63.68$63.24 – $64.184
FY30$5.1B$5.1B – $5.2B$71.24$70.76 – $71.814

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.98%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+12.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+21.5%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 19.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.195-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 27Patrick KaltenbachCEO942 sh$1.3MSellAug 5Thomas P SaliceDirector417 sh$601KSellAug 3Thomas P SaliceDirector415 sh$600KSellAug 3Gerry KellerHead of Process Analytics240 sh$343KSellAug 3Shawn VadalaCFO2.2K sh$3.2M
+ 12 other (7 awards · 5 exempts) in window

See when $MTD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 53
AI summary

Natalia Shuman-Fabbri filed an initial Form 3 on August 5, 2026, reporting her appointment as a Director of Mettler-Toledo International Inc. (MTD) as of August 3, 2026. She beneficially owns no Mettler-Toledo securities at the time of filing. This is a routine Section 16 administrative filing confirming the addition of a new board member to the Swiss-headquartered precision instruments and laboratory equipment company; it carries no financial or strategic implications.

8-KOfficer or director changeAug 38-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Mettler-Toledo International Inc. appointed Natalia Shuman as an independent director effective August 3, 2026, expanding the board from nine to ten members; committee assignments have not yet been determined. Ms. Shuman's compensation will be consistent with other independent directors as described in the March 2026 proxy. Routine administrative board expansion, with no financial impact.

8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change
AI summary

MTD disclosed a personnel change (8-K Item 5.02, dated 2026-05-13). A new executive or director appointment is reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

8-KShareholder voteMay 118-K — Item 5.07: Shareholder vote
AI summary

MTD held its annual meeting of stockholders around 2026-05-11 (8-K Item 5.07). The meeting was adjourned, likely due to insufficient quorum. Routine governance event — monitor for unusually high withhold votes as an activist signal.

+ 9 other (3 13Gs · 2 10-Qs · 2 earnings 8-Ks · 1 11-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Mettler-Toledo International Inc. to Host Investor Meetingbusinesswire.com·3d agoMettler-Toledo (MTD) Upgraded to Buy: What Does It Mean for the Stock?zacks.com·3d agoMettler-Toledo International Inc. to Host Third Quarter 2026 Earnings Conference Callbusinesswire.com·6d agoMettler-Toledo International (NYSE:MTD) Sets New 52-Week High – Here’s Whydefenseworld.net·9d agoAnalyzing Codexis (NASDAQ:CDXS) and Mettler-Toledo International (NYSE:MTD)defenseworld.net·22d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Medical - Diagnostics & Research

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$NEO$A$ILMN$TMO$GH$NTRA$DHR$GRAL
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport